You are here

A Study To Understand How The Body Reacts To A Low Dose Of PF‑06427878 When Given In A Vein To Healthy, Adult, Males

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Quotient Clinical Ltd
Ruddington, Nottingham, NG11 6JS United Kingdom
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Healthy
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Healthy male subjects between 18-55 years of age

2. BMI of 17.5-30.5 kg/m2

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. History of drug or alcohol abuse within 2 years of screening

2. Subjects without suitable veins for multiple venipuncture/cannulation

NCT02237742
Pfizer
Completed
A Study To Understand How The Body Reacts To A Low Dose Of PF‑06427878 When Given In A Vein To Healthy, Adult, Males

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Healthy Subjects
NCT03492697
All Genders
18+
Years
New Haven, Connecticut
Healthy Volunteers
NCT03184168
Males
18+
Years
Madison, Wisconsin
Healthy Subjects
NCT02637193
All Genders
18+
Years
New Haven, Connecticut
A Study To Understand How The Body Reacts To A Low Dose Of PF?06427878 When Given In A Vein To Healthy, Adult, Males
A Phase 1, Non?Randomized, Open?Label, Single?Dose, Single Period Study With Non?Pharmacologically Active Dose Of Pf?06427878 To Characterize Pharmacokinetics Following Intravenous Administration In Healthy, Adult, Male Subjects
To determine how the body reacts to a low dose of PF?06427878 when given in a vein over 30 minutes to healthy, adult, males.
Not Provided
Interventional
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Healthy
Drug: PF-06427878
Intravenous, 100 micrograms, single dose, 30 minute infusion
Experimental: PF-06427878
Intervention: Drug: PF-06427878
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
6
December 2014
November 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Healthy male subjects between 18-55 years of age
  2. BMI of 17.5-30.5 kg/m2

Exclusion Criteria:

  1. History of drug or alcohol abuse within 2 years of screening
  2. Subjects without suitable veins for multiple venipuncture/cannulation
Sexes Eligible for Study: Male
18 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT02237742
B7871004
2014-002626-12 ( EudraCT Number )
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2014

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now